ILF3

Chr 19p13.2

interleukin enhancer binding factor 3

Aliases:: NF90, MPHOSPH4, MPP4, NFAR-1, NFAR110
MANE:: ENST00000588657.6

OMIM: 603182 ↗NCBI: 3609 ↗Ensembl ↗

Annotations refreshed 9 hours ago.

Predicted protein structure

AlphaFold predicted structure

ILF3 · Q12906

v62025-08-01

Predicted Aligned Error matrix for ILF3 — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

66.8/ 100

Low

894 residues

Confidence breakdown

Very high(≥ 90)42%
Confident(70–90)9%
Low(50–70)4%
Very low(< 50)45%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Moderate Evidence (Amber)

COVID-19 research
Unknown

Disease associations (Open Targets)

neurodegenerative disease
0.46
Parkinson disease
0.37
osteoarthritis
0.37
Alzheimer disease
0.36
multiple sclerosis
0.36
lysosomal storage disease
0.36
Knee pain
0.28
osteoarthritis, knee
0.25
substance-related disorder
0.23
familial hypercholesterolemia
0.19

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Interleukin enhancer-binding factor 3

RNA-binding protein that plays an essential role in the biogenesis of circular RNAs (circRNAs) which are produced by back-splicing circularization of pre-mRNAs. Within the nucleus, promotes circRNAs processing by stabilizing the regulatory elements residing in the flanking introns of the circularized exons. Plays thereby a role in the back-splicing of a subset of circRNAs (PubMed:28625552). As a consequence, participates in a wide range of transcriptional and post-transcriptional processes. Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs (PubMed:14731398). Upon viral infection, ILF3 accumulates in the cytoplasm and participates in the innate antiviral response (PubMed:21123651, PubMed:34110282). Mechanistically, ILF3 becomes phosphorylated and activated by the double-stranded RNA-activated protein kinase/PKR which releases ILF3 from cellular mature circRNAs. In turn, unbound ILF3 molecules are able to interact with and thus inhibit viral mRNAs (PubMed:21123651, PubMed:28625552)